Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;189(1):54-66.
doi: 10.1111/bjh.16428. Epub 2020 Feb 17.

The new biology of PTCL-NOS and AITL: current status and future clinical impact

Matthew A Timmins  1 , Simon D Wagner  1 , Matthew J Ahearne  1
Affiliations
Review

The new biology of PTCL-NOS and AITL: current status and future clinical impact

Matthew A Timmins et al. Br J Haematol. 2020 Apr.

Abstract

Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of aggressive lymphoproliferative disorders almost all of which are associated with poor clinical outcomes. Angioimmunoblastic T-cell lymphoma (AITL) and some peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) have similarities to normal CD4+ T-cell subsets in their gene expression profiles. A cell of origin model is, therefore, emerging and is likely to be refined in the future. Follicular helper (Tfh) T cells are now established as the cell of origin of AITL and about 20% of PTCL-NOS. Sequencing studies have identified recurrent genetic alterations in epigenetic modifiers, T-cell receptor signalling pathway intermediates or RHOA, most commonly a specific mutation leading to RHOA G17V. While PTCL-NOS remains a diagnosis of exclusion, advances in genomics have identified subgroups expressing transcription factors TBX 21 (Th1-like origin) and GATA3 (Th2-like origin). These findings suggest new biomarkers and new therapeutic avenues including the hypomethylating agent azacytidine, or inhibitors of proximal T-cell receptor (TCR) signalling and potentially certain monoclonal antibodies. The advances over the past few years, therefore, prompt stratified medicine approaches to test biologically based treatments and determine the clinical utility of the new disease classifications.

Keywords: T helper cell; T-cell receptor; angioimmunoblastic T-cell lymphoma; epigenetics; peripheral T-cell lymphoma.

PubMed Disclaimer

References

    1. Agostinelli, C., Rizvi, H., Paterson, J., Shende, V., Akarca, A.U., Agostini, E., Fuligni, F., Righi, S., Spagnolo, S., Piccaluga, P.P., Clark, E.A., Pileri, S.A. & Marafioti, T. (2014) Intracellular TCR-signaling pathway: novel markers for lymphoma diagnosis and potential therapeutic targets. The American Journal of Surgical Pathology, 38, 1349-1359.
    1. Ahearne, M.J., Allchin, R.L., Fox, C.P. & Wagner, S.D. (2014) Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment. British Journal of Haematology, 166, 326-335.
    1. Allchin, R.L., Kelly, M.E., Mamand, S., Doran, A.G., Keane, T., Ahearne, M.J. & Wagner, S.D. (2019) Structural and diffusion weighted MRI demonstrates responses to ibrutinib in a mouse model of follicular helper (Tfh) T-cell lymphoma. PLoS ONE, 14, e0215765.
    1. Ansel, K.M., McHeyzer-Williams, L.J., Ngo, V.N., McHeyzer-Williams, M.G. & Cyster, J.G. (1999) In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines. The Journal of Experimental Medicine, 190, 1123-1134.
    1. Attygalle, A., Al-Jehani, R., Diss, T.C., Munson, P., Liu, H., Du, M.-Q., Isaacson, P.G. & Dogan, A. (2002) Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood, 99, 627-633.

MeSH terms

LinkOut - more resources